PMID- 31008526
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 146
IP  - 4
DP  - 2020 Feb 15
TI  - Perfluorinated alkylated substances serum concentration and breast cancer risk: 
      Evidence from a nested case-control study in the French E3N cohort.
PG  - 917-928
LID - 10.1002/ijc.32357 [doi]
AB  - Endocrine-disrupting chemicals are proposed to increase breast cancer (BC) 
      incidence. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), 
      two perfluorinated alkylated substances (PFASs), are suspected to be ubiquitously 
      present in the blood of human population worldwide. We investigated the 
      associations between serum concentrations of these substances and BC risk. Etude 
      Epidemiologique aupres de femmes de l'Education Nationale is a cohort of 98,995 
      French women born in 1925-1950 and followed up since 1990. We sampled 194 BC 
      cases and 194 controls from women with available blood samples. Serum 
      concentrations of PFASs were measured by liquid chromatography coupled to tandem 
      mass spectrometry (LC-MS/MS). Adjusted conditional logistic regression models 
      were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). All 
      statistical tests were two sided. While PFASs concentrations were not associated 
      with BC risk overall, we found positively linear associations between PFOS 
      concentrations and the risk of ER+ (3rd quartile: OR = 2.22 [CI = 1.05-4.69]; 4th 
      quartile: OR = 2.33 [CI = 1.11-4.90]); P(trend) = 0.04) and PR+ tumors (3rd 
      quartile: OR = 2.47 [CI = 1.07-5.65]; 4th quartile: OR = 2.76 [CI = 1.21-6.30]; 
      P(trend) = 0.02). When considering receptor-negative tumors, only the 2nd 
      quartile of PFOS was associated with risk (ER-: OR = 15.40 [CI = 1.84-129.19]; 
      PR-: OR = 3.47 [CI = 1.29-9.15]). While there was no association between PFOA and 
      receptor-positive BC risk, the 2nd quartile of PFOA was positively associated 
      with the risk of receptor-negative tumors (ER-: OR = 7.73 [CI = 1.46-41.08]; PR-: 
      OR = 3.44 [CI = 1.30-9.10]). PFAS circulating levels were differentially 
      associated with BC risk. While PFOS concentration was linearly associated with 
      receptor-positive tumors, only low concentrations of PFOS and PFOA were 
      associated with receptor-negative tumors. Our findings highlight the importance 
      of considering exposure to PFASs as a potential risk factor for BC.
CI  - (c) 2019 UICC.
FAU - Mancini, Francesca Romana
AU  - Mancini FR
AUID- ORCID: 0000-0003-2297-3869
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
FAU - Cano-Sancho, German
AU  - Cano-Sancho G
AD  - UMR INRA-Oniris 1329 LABERCA, Nantes, France.
FAU - Gambaretti, Juliette
AU  - Gambaretti J
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
FAU - Marchand, Philippe
AU  - Marchand P
AD  - UMR INRA-Oniris 1329 LABERCA, Nantes, France.
FAU - Boutron-Ruault, Marie-Christine
AU  - Boutron-Ruault MC
AUID- ORCID: 0000-0002-5956-5693
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
FAU - Severi, Gianluca
AU  - Severi G
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
FAU - Arveux, Patrick
AU  - Arveux P
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
AD  - Breast and Gynaecologic Cancer Registry of Cote d'Or, Georges-Francois Leclerc 
      Cancer Centre, UNICANCER, Dijon, France.
FAU - Antignac, Jean-Philippe
AU  - Antignac JP
AD  - UMR INRA-Oniris 1329 LABERCA, Nantes, France.
FAU - Kvaskoff, Marina
AU  - Kvaskoff M
AUID- ORCID: 0000-0002-4557-3772
AD  - CESP, Fac. de medecine, Univ. Paris-Sud, Fac. de medecine - UVSQ, INSERM, 
      Universite Paris-Saclay, Villejuif, France.
AD  - Gustave Roussy, Villejuif, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190503
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Alkanesulfonic Acids)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Caprylates)
RN  - 0 (Fluorocarbons)
RN  - 947VD76D3L (perfluorooctanoic acid)
RN  - 9H2MAI21CL (perfluorooctane sulfonic acid)
SB  - IM
MH  - Age Factors
MH  - Alkanesulfonic Acids/*blood
MH  - Biomarkers, Tumor/blood
MH  - Breast Neoplasms/*blood/epidemiology
MH  - Caprylates/*blood
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Female
MH  - Fluorocarbons/*blood
MH  - France/epidemiology
MH  - Humans
MH  - Middle Aged
MH  - Risk
OTO - NOTNLM
OT  - E3N cohort
OT  - breast cancer
OT  - nested case-control study
OT  - perfluorooctane sulfonate (PFOS)
OT  - perfluorooctanoic acid (PFOA)
OT  - serum levels
EDAT- 2019/04/23 06:00
MHDA- 2020/02/20 06:00
CRDT- 2019/04/23 06:00
PHST- 2018/11/14 00:00 [received]
PHST- 2019/04/01 00:00 [revised]
PHST- 2019/04/11 00:00 [accepted]
PHST- 2019/04/23 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2019/04/23 06:00 [entrez]
AID - 10.1002/ijc.32357 [doi]
PST - ppublish
SO  - Int J Cancer. 2020 Feb 15;146(4):917-928. doi: 10.1002/ijc.32357. Epub 2019 May 
      3.